35 results
8-K
EX-99.1
STRO
Sutro Biopharma Inc
10 Aug 23
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:31pm
significant interest of luvelta within the medical community, providing momentum for patient enrollment into REFRaME across our global sites," said Bill
PRE 14A
vvfd2z23z9x
14 Apr 23
Preliminary proxy
4:05pm
8-K
EX-99.1
eb70 c7i2s
19 May 21
Regulation FD Disclosure
5:00pm